A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin) in Patients With Solid Tumors

Trial Profile

A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin) in Patients With Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs ME 344 (Primary) ; Topotecan
  • Indications Cervical cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors MEI Pharma
  • Most Recent Events

    • 10 Mar 2017 Results published in the Investigational New Drugs
    • 05 Jul 2016 Status changed from completed to discontinued due to lack of efficacy.
    • 21 Apr 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top